Table 2. Reported clinical activity of GITR agonists being evaluated in ongoing or completed clinical trials.

Agent (Sponsor)	Tumor type	Combination	Phase	Status	NCT.GOV ID	Single-agent activity	Combination activity	Primary publication
Monospecific agonistic antibody
AMG-228 (Amgen)	All solid tumors	Not observed	I/II	Completed	NCT02437916	Not reported	Not applicable	Tran et al. [50]
ASP1951 (Astellas)	All solid tumors	Pembrolizumab	I/II	Active, not recruiting	NCT03799003	Not reported	Not reported	Not reported
BMS-986156 (Bristol-Myers Squibb)	All solid tumors	Nivolumab	I/II	Completed	NCT02598960	Not reported	Reported	Heinhuis et al. [47]
	Metastatic tumors in the liver or lung	Ipilimumab/nivolumab +/− SBRT	I/II	Active, not recruiting	NCT04021043	Not reported	Not reported	Not reported
GWN323 (Novartis)	All solid tumors and lymphomas	Spartalizumab	I/II	Completed	NCT02740270	Not reported	Reported	Piha-Paul et al. [49]
INCAGN1876 (Incyte)	All solid tumors	N/A	I/II	Completed	NCT02697591	Not reported	Not reported	Not reported
	All solid tumors	Ipilimumab or nivolumab	I/II	Completed	NCT03126110	Not reported	Not reported	Not reported
	Recurrent glioblastoma	Retifanlimab	II	Active, not recruiting	NCT04225039	Not reported	Not reported	Not reported
MK-1248 (Merck)	All solid tumors	Not observed	I/II	Completed	NCT02553499	Not reported	Reported	Geva et al. [46]
MK-4166 (Merck)	All solid tumors	Pembrolizumab	I	Completed	NCT02132754	Not reported	Reported	Papadopoulos et al. [48]
REGN6569 (Regeneron)	All solid tumors	Cemiplimab	I	Active, recruiting	NCT04465487	Not reported	Not reported	Not reported
TRX518 (Leap Therapeutics)	All solid tumors	Anti-PD-1 nivolumab, pembrolizumab and chemotherapy	I/II	Completed	NCT02628574	Reported	Reported	Davar et al. [45]
Co-stimulatory GITR ligand
MEDI1873 (AstraZeneca)	All solid tumors	Not studied	I	Completed	NCT02583165	No objective responses (prolonged stable disease)	N/A	Balmanoukian et al. [44]